Meg Jardine's Publications

About Meg Jardine's Publications

Honorary Professorial Fellow, The George Institute for Global Health
  • Associate Professor, Faculty of Medicine, UNSW Sydney
  • Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes

    Journal of the American College of Cardiology Date published:
  • Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy

    Kidney International Reports Date published:
  • Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial

    BMJ Open Date published:
  • Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: a participant level pooled analysis of CREDENCE and CANVAS

    European Heart Journal Date published:
  • Bidirectional relationship between kidney disease progression and cardiovascular events in type 2 diabetes: new Insights from the CANVAS Program and CREDENCE trial

    European Heart Journal Date published:
  • Canagliflozin and iron metabolism in the CREDENCE trial

    Nephrology Dialysis Transplantation Date published:
  • Adaptive Designs for Clinical Trials in Nephrology

    Journal of the American Society of Nephrology Date published:
  • Vascular Endothelial Growth Factor-B Blockade with CSL346 in Diabetic Kidney Disease

    Journal of the American Society of Nephrology Date published:
  • Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials

    The Lancet Diabetes & Endocrinology Date published:
  • Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From 4 Large-Scale Placebo-Controlled Outcome Trials

    Circulation Date published:
  • Heart failure events in randomized controlled trials for adults receiving maintenance dialysis: a meta-epidemiologic study

    Nephrology Dialysis Transplantation Date published:
  • The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy

    Kidney International Reports Date published:
  • Adherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care

    Diabetes Research and Clinical Practice Date published:
  • Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial

    European Journal of Heart Failure Date published:
  • Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis

    Circulation Date published:
  • IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial

    Nature Medicine Date published: